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Structure validation is a key component of all steps in the structure determination process, from structure
building, refinement, deposition, and evaluation all the way to post-deposition optimisation of structures in the
Protein Data Bank (PDB) by re-refinement and re-building. Today, many aspects of protein structures are
understood better than 10 years ago, and combined with improved software and more computing power, the
automated PDB_REDO procedure can significantly improve about 85% of all X-ray structures ever deposited
in the PDB. We review structure validation, structure improvement, and a series of validation resources and
facilities that give access to improved PDB files and to reports on the quality of the original and the improved
structures. Post-deposition optimisation generally leads to improved protein structures and a series of
examples will illustrate how that, in turn, leads to improved or even novel biological insights.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
In 1951, Pauling and Corey predicted the α-helix [1]
and the β-sheet [2]. In 1958, the first picture of a protein
was obtained when Kendrew and colleagues solved
the structure of myoglobin at 6 Å using X-ray crystal-
lography [3]. In 1960, the structure of myoglobin was
obtained at 2 Å [4] and the structure of haemoglobin
was solved [5]. The similarity between the tertiary
structures of haemoglobin and myoglobin showed the
evolutionary conservation of the globin folds [6,7], and
these structures “laid the foundation” [8] for under-
standing the mechanism of cooperativity in haemoglo-
bin and hinted already at the possibility to perform
homology modelling, which was performed for the first
time when α-lactalbumin was modelled based on the
crystal structure of hen egg-white lysozyme 4 years
later [9]. Myoglobin and haemoglobin illustrate the
impact of protein atom coordinates on science in
general and on biology in particular. Kendrew and
Perutz received for their work a Nobel Prize, an honour
later also bestowed on scientists† for (structure) work
on G protein-coupled receptors, the ribosome, insulin,Authors. Published by Elsevier Ltd. T
rg/licenses/by/4.0/).the photosynthetic reaction centre, ATPase, GFP,
ubiquitin, ion and water channels, protein structure
NMR in general, and for computational techniques on
protein structures. The last of this list was awarded for
“the development of multiscale models for complex
chemical systems”, which is a computational technique
that critically depends on the accuracy of the protein
structure coordinates.
Novotný, Bruccoleri, and Karplus were the first to ask
whether correctly folded protein models could be
distinguished from incorrectly folded protein models
[10,11]. They modelled the sequence of the α-helical
sea worm haemerythrin on the mainly β-stranded
mouse immunoglobulin VL domain and vice versa. The
incorrect side chains could be incorporated reasonably
well and the empirical potential energy of these
mis-folded models was comparable to the correct
models. The mis-folded models, however, had higher
non-covalent energy terms, a larger solvent-accessible
surface area, and more exposed non-polar side-chain
atoms [10]. Others reported that, compared to the
correct models, the incorrect models have a lower
solvation free energy [12], are less compact [13], andhis is an open access article under the CC BY license
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1376 Review: Better Structure Modelsmake only about half as many hydrophobic contacts
[14]. These deliberately mis-folded proteins have long
served to validate protein structure analysis and
validation methods [12–24].Validation
It is generally believed that the field of protein
structure validation came into existence in 1989 when
serious errorswerediscovered in a series of depositedFig. 1. Threading errors in protein structures. (a) The best
PDBentry 5fd1 [25] (orange) and themis-threaded [26]PDBentry
the correct PDB entry 5p21 [28]. These two β-strands were trace
reported inRef. [30]. (c) The small subunits of spinachRuBisCoa
RuBisCo subunit was threaded incorrectly [32] in the structure
structures 1enl [34] (grey) and 2enl [35] (orange). The firstβ-stran
the correct structuremodel 2enl. The 1enl structuremodel is trace
atoms (ball-and-sticks) are incorrectly assigned to theC-terminus
(spheres), resulting in an erroneous dimer interface [37]. The pro
C-terminal connection (scissors) with the stretch of five Cα atoms
The symmetry-related copy is shown in purple. Figures were prcrystal structures (seeFig. 1). These discoveries led to
the Collaborative Computational Project Number 4
study weekend “Accuracy and reliability of macromo-
lecular crystal structures” and Brändén and Jones
subsequently published their seminal commentary on
errors and checks to detect them [39]. Soon after this
commentary was published, the crystallographic
model-building program O could compare rotamers
and the position of backbone oxygen atoms to
database penta-peptides [40]. The protein structure
bioinformatics community also took up the challengesuperposition possible for ferredoxin I in the correctly traced
2fd1 [27] (grey). (b)β-Strandsβ1 (yellow) and β3 (orange) in
d in each other's density [29] in the structure of human p21
re coloured in the correct structuremodel 1rcx [31]. The small
reported in Ref. [33]. (d) Residues 143–203 of the enolase
d is followed by a loopand ananti-parallel second β-strand in
d backwards. (e) In theCα-only PDB entry 2hvp [36], fiveCα
of theHIV-1 protease rather than correctly to theN-terminus
blem can be resolved (PDB entry 3hvp [37]) by breaking the
and connecting (glue) the stretch to the N-terminus instead.
epared with CCP4mg [38].
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methods were published in rapid succession:
Directional Atomic Contact Analysis (DACA [21]),
PROCHECK [41], and Protein Structure Analysis
(ProSA [23]) were published. These three methods
determined rules from protein structures solved at high
resolution—that are therefore presumed “correct”—to
find errors in protein structures in general.
Vriend and Sander determined a contact quality
index that measures the agreement between the atom
distributions of all possible close contacts in the
structure model and equivalent database distributions
[21]. This detailed evaluation of atomic packing also
allows for the detection of local errors in the protein
packing. This method was implemented in WHAT IF
[42]. The quality index resulting from this analysis is
now known as packing quality or DACA inWHAT_CH-
ECK [43].
Thornton and co-workers described the stereochem-
ical quality of protein structures in terms of the
parameters derived by Morris et al. (Cα chirality,
disulfide bond length, proline φ, main-chain hydrogen
bond energy, peptide bond planarity, side-chain torsion
angles χ1 and χ2, etc.) [44], bond lengths and bond
angles [45], and position in the Ramachandran plot
[46]. These stereochemical checks were implemented
in PROCHECK [41].
Sippl applied the concept of potentials of mean force
[47] to Cα–Cα [23] and Cβ–Cβ [16,23] distances. In the
ProSA method, the pseudo-energy of proteins is
derived using a combination of mean force potentials,Fig. 2. Protein structures with improbable features. L
unusual and improbable features in a structure of the complem
contacts in the c-direction of the unit cell (grey) was the most
University of Alabama as to whether structures solved by H. K
unusual features was discovered by Rupp in 2012 [51]. The
modelled at zero occupancy; white: full occupancy) of PDB en
grid size of 0.1 Å) contoured at +1.0 σ (green) and at the nois
features noticed by Rupp was the complete absence of any 2m
levels whilst normal main-chain B-factors had been reported. T
model with zero occupancy atoms [51].and the mean field energy of a protein structure is
transformed into a Z-score by evaluating the energy for
a large number of structure decoys (alternative
conformations) as well [23].
More methods that give a score to a whole
molecule have been published; often, like ProSA,
in threading projects. Eisenberg and colleagues, for
example, calculated amino acid preferences as a
function of three-residue environment parameters
(the area of the residue that is buried, the fraction of
side-chain area that is covered by polar atoms, and
the local secondary structure) [48] and measured
the compatibility of a protein model with its
sequence using this so-called three-dimensional
profile [19].
Initially, protein structure validation was met with
some resistance from the protein structure determi-
nation field (e.g., see Ref. [53]), but some high-profile
cases of structure models with very unusual features
(see Fig. 2) led the protein structure communities—
structure determination and bioinformatics alike—to
start Validation Task Forces (VTFs) for X-ray crystal-
lography [54], NMR [55], and electron microscopy
[56]. The X-ray and NMR VTFs have written their
recommendations, and the wwPDB consortium [57] is
presently implementing these recommendations in
software that depositors of structures must use. It will
take time to implement all VTF recommendations; thus,
depositors who want to very extensively validate their
structure before deposition will still need, for a while, to
use tools such as WHAT_CHECK‡, MolProbity [58],eft: in 2006, Gros and colleagues [49] identified several
ent protein C3b (PDB entry 2hr0). The absence of crystal
improbable feature. This triggered an investigation by the
. M. Murthy were fabricated [50]. Right: another instance of
figure shows residues Val134 and Lys135 (red: atoms
try 3k78 [52] and the 2mFo − DFc map (calculated using a
e level +0.4 σ (blue). One of the highly improbably model
Fo − DFc density for unoccupied atoms down to near-noise
his suggested that the data were indeed calculated from a
1378 Review: Better Structure Modelsand CING [59] in addition to the Protein Data Bank
(PDB) [57,60] validation server [54,61].
Validation tools can be categorised in many ways;
for example, by their level of detail. Most of the older
tools give one score for the whole structure and
capture the overall quality of a structure in one
number. Although ProSA, PROCHECK, DACA, and
QMEAN [62,63], for example, score aspects of
individual residues, their strength lies in whole protein
quality evaluation. Validation tools also can be
categorised by the certainty with which they can call
things right or wrong. Most validation options do not
determine the quality but merely the normality of a
protein structure, that is, how similar a protein
structure model is to a collection of good, high--
resolution structures in terms of the validation
parameters. Other validation options (noticeably, all
nomenclature checks, many administrative validation
options, and routines that calculate the agreement of a
model with the experimental data) provide answers
about quality rather than normality. The Cambridge
Structural Database (CSD) [64] holds more than
700,000 structures of small molecules that have
been solved at much higher resolution than most
PDB entries. Geometric parameters that can be
determined froman analysis ofCSD files are therefore
so accurate that they can be used for all practical
purposes as a gold standard when solving or
validating PDB entries. The prime example of
CSD-derived parameters are the famous Engh and
Huber bond length and bond angle data [45,65] that
are still used today in most refinement and validation
software. Similarly, Hooft et al. used the CSD to
determine the normal deviation from planarity in
planar groups in proteins [66].
Global scores can detect bad structure models but
they are not very useful when validation is used to
actually improve model quality. Many tools, fortu-
nately, detect erroneous molecular details that can
be used directly to improve the quality of structures.
Hooft et al. used the CSD to arrive at a force field
for hydrogen bond energies and used this force field
to optimise the flipping of Asn, Gln, and His side
chains [67]. Hydrogen bond network optimisation is
part of WHAT_CHECK [43] and MolProbity [68].
Nielsen showed the importance of this validation-
based structure improvement for electrostatic calcu-
lations [69,70], and the realisation that a series of
measured pKa values commonly used for the
calibration of electrostatic computation methods
were flawed by crystal packing artefacts dramatically
improved the entire field of protein electrostatics [70].
Nielsen also showed that electrostatic calculations
for most enzymes in the PDB would give significantly
better results if the hydrogen bonding network would
be improved prior to the calculations [69].
Wrong cell dimensions lead to systematic devia-
tions in bond lengths and angles. Hooft et al. wrote
software that projects the protein's bond lengths andangles on the axis system of the crystal cell to correct
the cell's dimensions [71]. Lamzin and co-workers
later improved this method [72].
The growth of the PDB has allowed validation of the
Ramachandran plot [58,73] and bond lengths and
angles [74,75] to become specific for secondary
structure and residue type. Rotamer libraries con-
structed using high-resolution protein structures
[40,76–79] are used in several programs to perform
a knowledge-based validation of side-chain confor-
mation. Misfit side chains may also be detected by Cβ
position deviations [80] and steric clashes [43,58]. The
RosettaHoles software provides a validation score for
under-packing [81].
Several groups have developed tools such as
VHELIBS [82], ValLigURL [83], Mogul [84], and
Twilight [85] to visualise and validate ligands; tools
such as pdb-care [86], CARP [87], and Privateer
[88,89] to check carbohydrates [90,91]; and pro-
grams such as ERRASER [92] to re-build nucleic
acids and MolProbity [58] to validate nucleic acids.
CH4, NH3, NH4
+, H2O, OH
−, Ne, Na+, Mg2+, and
Al3+ all contain 10 electrons and thus will scatter
X-rays roughly equally much. This makes it hard to
see the difference between them in any electron
density determined at worse than atomic resolution.
The same problem exists for K+ and Ca2+ that both
have 18 electrons. Moreover, K+ and Ca2+ at
half-occupancy scatter X-rays roughly equally
much as H2O, Na
+, Mg2+, and so on. Consequently,
many ions in the PDB are of the wrong type or
actually should be water, whilst many waters should
be ions [93]. Brown has determined empirical bond
valence parameters [94,95] that can be used to
determine the ion type from the distances between
the ion and its coordinating atoms. This method
works reasonably well but only at high resolution
when all surrounding atoms can be seen very well in
the density and when there is no bias caused by
refining ion X as ion Y forcing ion X to get the
ligand-atom distances of ion Y. The Brown param-
eters have been implemented in SHELX [96] and
WHAT_CHECK (unpublished results) and, later
also, in CheckMyMetal [97] and Phenix [98].
Alkali and alkaline earth metals are preferentially
coordinated by oxygen atoms and not by nitrogen
atoms. Dauter et al. recently reported that calcium
ions in the so-called strong calcium site of several
savinase structure models seem to be coordinated by
the nitrogen atom instead of the oxygen atom of an
asparagine [99]. A pseudo-octahedral calcium site is
normally coordinated by oxygen atoms only. The
B-factors of the Asn suggested that the side chain
should be flipped. An inspection of the PDBREPORT
database [43] reveals that the chemically highly
implausible coordination of sodium, potassium, calci-
um, or magnesium ions by the nitrogen atom instead
of the oxygen atom in asparagine or glutamine side
chains occurs in 327 sites in 269 PDB entries,
Fig. 3. Asn side-chain flips at atomic resolution.
Sodium-binding site of glycinamide ribonucleotide trans-
formylase (PDB entry 1kjq, determined at 1.05 Å resolu-
tion [100]). The side chain of Asn100 has a highly unlikely
conformation because the nitrogen rather than the oxygen
coordinates the ion. PDB_REDO flips the side chain so
that the ion is coordinated by the side-chain oxygen. The
PDB files of several hundred incorrect sites similar to this
site contain LINK records specifying the N-metal coordi-
nation. Incorrect LINK records between the nitrogen of Asn
and Gln side chains and Na+, Mg2+, K+, and Ca2+ are
removed, allowing structure correction by side-chain
re-building (since PDB_REDO version 5.37). Future
versions of PDB_REDO will also flip metal coordinating
side chains based on results from WHAT_CHECK.
1379Review: Better Structure Modelsincluding the savinase example and several struc-
tures solved at atomic resolution (Fig. 3).
Several authors have noted an under-representa-
tion of cis peptides in the PDB that is partly the result
of the a priori assumption in structure determination
that all peptides have a trans conformation [101–
104]. Trans peptide planes have also been observed
rotated by 180°; this is called a peptide plane flip.
Peptide plane flips typically are the result of mistakes
in the early stages of model building when the
electron density maps are not yet very clear. An
incorrectly built peptide plane tends to lead to locally
distorted geometry. We recently designed a ran-
dom-forest-based method to detect these problems
[105] and found almost 5000 trans–cis errors and
many thousands of peptide plane flips.Improving PDB files by re-refinement
and re-building
Over the years, 3299 PDB entries have been
made obsolete. Most times, these entries were
made obsolete because a better version became
available, for example, based on higher-resolutiondata, but sometimes, the entries were highly
improbable and made obsolete without putting a
replacement file in the PDB. We also see more and
more cases of PDB files that were improved and
deposited by others than the original authors. In
2007, Joosten and Vriend took a more systematic
approach and re-refined some 1200 structure
models for which data were available to 2.00 Å
resolution [106]. More than three-quarters of the
re-refinedmodels had an improvedR-free value and
improved geometric characteristics. After this suc-
cessful small-scale proof of concept, Joosten et al.
re-refined all high- and medium-resolution X-ray
structures in the PDB (15,000 at the time) for which
the reflection data (including the R-free set) were
deposited and useful [107]. They showed that,
despite the complication of using many more low--
resolution models, two-thirds of the re-refined
models were improved in terms of R-free [107].
The Ramachandran Z-score of the structure models
also improved over the entire resolution range. In
addition, they showed that the possibility of improv-
ing published structure models was not limited to old
structure models but that more than 60% of recently
deposited structure models could also be improved.
The addition of side-chain re-building and peptide--
flipping tools [108] plus more advanced refinement
parameterisation algorithms improved the success rate
of PDB_REDO and extended the scope to active
correction of modelling errors or, more poetically,
“constructive validation” [109]. The specific
PDB_REDOsteps that are applied based on validation
algorithms are described in Table 1. Analyses ofR-free
and six WHAT_CHECK model-quality metrics of
12,000 randomly chosen PDB entries show that 85%
of the PDB entries can be improved in terms of overall
quality [109].
The re-refined structure models (plus electron
density maps and a multitude of metadata) are
stored in the PDB_REDO databank [112,113]. This
repository now holds 99% of all crystallographic
PDB entries for which experimental data are
deposited (currently more than 90,000). New entries
are added automatically with every new PDB
release. Older PDB_REDO entries are replaced
gradually or whenever a PDB entry is re-released,
typically because of changes in the entry's annota-
tion. It should be noted that many changes in
annotation of PDB entries are the result of the
PDB_REDO project. Over the course of the project,
nearly 7500 annotation problems that somehow
hampered the optimisation or interpretation of PDB
entries were reported and the PDB staff corrected
the majority of these.
In an automated procedure, there is always a risk
of introducing errors. A particularly difficult step is
the restraint generation for ligands. This relies on
reasonable input coordinates of a ligand, correct
annotation of the chemistry by the PDB and/or
Table 1. Validation-driven PDB_REDO steps
PDB_REDO step Programs involved
Removal of improbable (metal coordination) LINKs Stripper [109]
Correction of carbohydrate LINK topology Stripper
Correction of carbohydrate names pdb-care [86] and stripper
Removal of superfluous carbohydrate oxygens pdb-care and stripper
Removal of improbable ligand occupancy models REFMAC [110]
Removal of overly detailed B-factor models REFMAC and Bselect [109]
Correction of atomic chirality problems REFMAC, WHAT_CHECK [43], and Chiron [109]
Addition of missing side-chain atoms SideAide [108] and DSSP [111,112]
Histidine, asparagine, and glutamine flips to improve hydrogen bonding WHAT_CHECK and SideAide
Peptide flipping Pepflip [108] and DSSP
Removal of waters not supported by the electron density Centrifuge [108]
1380 Review: Better Structure Modelsproper interpretation of the coordinates by the tools
in PDB_REDO. Although ligands generally improve
slightly in PDB_REDO [82], sometimes ligands are
refined incorrectly. It is therefore highly recommend-
ed to critically inspect ligands and their electron
density manually, which is, by the way, not different
for original PDB entries [83,85,114,115].
Taken together, the PDB_REDO procedure typi-
cally leads to structure models that better fit their
experimental data, have more plausible molecular
geometry, and are more informative for biological
interpretation.Better biology through better structure
models
Four decades after Browne's first attempt at homol-
ogy modelling on α-lactalbumin, the technique has
become a research field in itself, and much effort is
directed towards selecting goodmodels froma large set
of candidates (e.g., see Ref. [116] and references
therein). Using both PDB templates and PDB_REDO
templates, we built homology models with YASARA for
33 CASP11 targets for which the alignment is
essentially certain whilst small structural details are
important (best GDT_TS N 60%) [116]. We found that
the average Cα root-mean-square (RMS) error was
reduced from 2.28 Å (using PDB templates) to 2.15 Å
(using PDB_REDO templates). The average Cα RMS
deviation between PDB and PDB_REDO structure
models is 0.15 Å. These results suggest that the use of
PDB_REDO templates certainly does not harm the
homology modelling process and that the changes
made by PDB_REDO are improvements in the right
direction.
Better template structures thus lead to better
homology models, and both better structure
models and better homology models obviously
must lead to better answers to biological questions.
Sometimes corrections in PDB files do not influ-
ence the biology; a bond length correction by
0.18 Å, for example, is crystallographically signif-
icant but will not change the answer to a questionrelated to mutability, antigen selection, or intermo-
lecular interactions. Other corrections though, for
example, replacing a calcium ion near the active site
by a zinc or flipping the side chain of asparagine in
the ligand binding pocket, are likely to lead to
radically different and more reliable answers to
questions related to understanding an enzyme's
mechanism or drug design.
The next 10 sections review examples of “better
biology through better structures”. In each example,
improvement of the PDB file led to a different view on
the biological role of a molecule or to a different
answer to a biological question.Example 1—Peptide plane flip in Plk1
Polo Box Domain substrate
García-Álvarezet al. reported the structureof thePolo
Box Domain (PBD) of the human serine/threonine
kinase Plk1 in complex with a 9-mer phosphopeptide
substrate derived from Cdc25C (PDB entry 2ojs [117]).
Plk1 is essential for regulating cell cycle progression
and is an important drug target for cancer therapy [118].
They discuss the molecular mechanisms of substrate
recognition of Plk1 and the implications for the
centrosomal localisation and activity.
The PDB_REDO program Pepflip detected that
the peptide plane between Leu1 and Leu2 of the
Cdc25C phosphopeptide should be flipped to
better fit the electron density and improve
the Ramachandran plot. In the correct conforma-
tion, there is an additional hydrogen bond between
the peptide and Asp416 in Plk1 (Fig. 4). Further-
more, after the peptide plane flip, the Cdc25C
peptide forms an additional β-strand, thereby
extending the β-sheet in Plk1. The substrate
conformation was corrected by the depositors
who obsoleted PDB entry 2ojs and superseded it
by PDB entry 3bzi. Free energy calculations using
the corrected phosphopeptide showed that the
phosphothreonine residue and the main-chain
atoms of the peptide account for the majority of
the binding enthalpy [119].
Fig. 4. Peptide plane flip in Plk1 PBD substrate. Left: the electron density around the peptide plane between Leu1
and Leu2 of the substrate (white carbons) suggests that the peptide should be flipped to allow a hydrogen bond to the
carbonyl of Asp416 in the enzyme (pink carbons) in PDB entry 2ojs [117]. Right: the peptide substrate extends the Plk1
β-sheet in the superseding entry 3bzi due to the flipped peptide plane. Unless mentioned otherwise, the 2mFo − DFc and
mFo − DFc maps have been sampled with a grid size equal to a third of the resolution and are shown at a contour level of
+1.2 σ (blue) and +3 σ (green) and −3 σ (red), respectively, and the entire model has been used for the calculated
structure factors. The 2mFo − DFc and mFo − DFc maps are shown up to 2 Å from the displayed peptide atoms.
1381Review: Better Structure ModelsThe extension of the β-sheet is an integral part of
the substrate recognition mechanism and is only
visible in the corrected structure.Example 2—Wishfully modelling a Plk1
PBD inhibitor
The Plk1 PBD binds to pThr/pSer-containing motifs
[120]. Qian et al. reported a Plk1 PBD structure in
complex with an inhibitor in the PBD pocket (PDB entry
4mlu [121]).Qianet al. designed the inhibitory peptide to
mimic a natural substrate but wanted to improve the
cellular uptake efficiency by making the inhibitory
peptidemono-anionic rather than di-anionic bymasking
the phosphothreonine. The mono-anionic phosphoe-
ster was fitted in the reported structure model 4mlu.
Dauter et al. discovered that the electron density
does not justify modelling the phosphoester moiety
(Fig. 5) [99]. Thus, the inhibitor is still di-anionic. Qian
et al. then retracted their paper and replaced the
phosphoester moiety by water in PDB structure 4o6w
that supersedes 4mlu (Fig. 5).
In summary, the design of PBD inhibitors that both
mimic the natural substrate and have drug-like
physicochemical properties is still an open challenge.Example 3—hPHMT ligand identification
Human phenylethanolamine N-methyltransfer-
ase (hPNMT) catalyses the conversion of R-nor-adrenaline into R-adrenaline. In this reaction, a
methyl group is transferred from the co-factor S-adeno-
syl-L-methionine to noradrenaline. PNMT inhibitors
specific to the central nervous systempotentially are
important drug targets for Alzheimer's and Parkinson's
diseases. In a fragment-based drug design screen,
Drinkwater et al. soaked hPNMT crystals with 96
mixtures of four chemically diverse small molecules
and modelled 12 hits in the electron density, 9 of which
were confirmed by isothermal titration calorimetry to
bind to hPNMT [122].
Nair et al. showed that molecular dynamics (MD)
simulations reproduced the crystal structure bind-
ing mode modelled for these nine compounds
[123]. For one of the other cocktails, Drinkwater et
al. proposed 6-chlorooxindole as the most likely
candidate for explaining the electron density
observed in the noradrenaline pocket (PDB entry
3kpy, Fig. 6), but they could not confirm binding by
isothermal titration calorimetry. The MD simula-
tions predicted that 6-chlorooxindole cannot stably
bind to hPNMT. In contrast, the simulations
suggested that the pocket was occupied by two
other fragments in the cocktail, benzene-1,3-diol
and imidazole. Free energy calculations predicted
the binding to be cooperative and re-refinement
showed that these two fragments together could
also account for the electron density (PDB entry
4dm3, Fig. 6).
The combined pharmacophores of benzene-1,3--
diol and imidazole provide a better basis for rational
Fig. 5. The phosphothreonine fragment of a PBD inhibitor in the structure of the human Plk1 is di-anionic rather
than mono-anionic. Left: although a disordered phosphoester moiety is modelled in PDB entry 4mlu [121], the electron
density suggests that this group is absent. Right: water molecules and a di-anionic inhibitor are modelled in the
superseding PDB entry 4o6w [121]. The 2mFo − DFc and mFo − DFc maps are shown up to 1.5 Å from the displayed
inhibitor fragment and water molecules.
1382 Review: Better Structure Modelsdesign and thus for the development of hPNMT
inhibitors.Example 4—Herceptin-HER2 interface
When over-expressed, human epidermal growth
factor receptor 2 (HER2, also known as ErbB2 and
Neu) can promote malignant cell transformation
[124]. The monoclonal antibody Trastuzumab,
commercially known as Herceptin, is known to
have an anti-proliferative effect on cells transformed
by over-expression of HER2 and is therefore used to
treat HER2-positive metastatic breast cancers
[125]. The structure of the Fab fragment of Herceptin
bound to the extracellular domain of HER2, PDB
entry 1n8z [126], shows the binding interface of the
two proteins. This indicates where Herceptin binds,
but as a result of poor side-chain fitting, the structure
model does not properly show how and why
Herceptin binds (Fig. 7).
Automated re-building of 1n8z reveals numerous
additional receptor–antibody interactions, resulting
in a much more faithful description of the binding
mode of Herceptin.
The better understanding of the binding mode of
Herceptin contributes to the development of other
monoclonal antibodies in cancer immunotherapy.Example 5—Ion identity in myosin heavy
chain kinase regulatory sites
Myosin II plays a central role in cytokinesis, cell
migration, and adhesion [127]. The α-kinase domainof myosin heavy chain kinase (A-CAT) is involved in
regulating the formation of myosin II filaments and
the active site of A-CAT undergoes a conformational
switch that is said to be influenced by the magne-
sium-binding sites [128].
Minor and co-workers recently implemented
Brown's bond valence method in the CheckMyMe-
tal web server [97] for the validation of metals in
macromolecular structures. They reported several
examples of mis-identified ions, amongst which the
magnesium ions in A-CAT (PDB entry 3lkm, [128]).
The validation results, the reported crystallisation
conditions, the sample preparation, and manual
re-refinement all suggest that one magnesium ion
should be replaced with water, whilst the other two
should be replaced by potassium and coordinated
also by ethylene glycol (Fig. 8) [97].
The presence of potassium rather than magne-
sium in the regulatory sites casts serious doubt on
the role of magnesium and suggests that the role of
potassium in regulating the activity of α-kinase is
worth investigating.Example 6—Trans–Cis isomerisation in
Rab4a switch 2 region
The Ras-like protein Rab4 is involved in endo-
somal sorting by orchestrating a small GTPase
cascade for recruitment of adaptor proteins to early
endosomes [129]. Despite the high level of se-
quence similarity between members of the Rab
family, each member targets specific effector
proteins. One of the molecular regions involved in
the discrimination between different effector
Fig. 6. Ligand identification in the hPNMT active site. The binding pocket is occupied by 6-chlorooxindole in PDB
entry 3kpy [122] (left) and with benzene-1,3-diol (in two alternative conformations) and imidazole in PDB entry 4dm3 [123]
(right). The binding modes of these two ligands were predicted by MD simulations [123]. The figure shows the possible
hydrogen bonds over time. The 2mFo − DFc map is shown up to 1.5 Å from the ligands.
1383Review: Better Structure Modelsproteins is theso-calledswitch2 region [130]. Theswitch
2 region is rearranged upon GTP hydrolysis. The
structure of humanRab4a has been solved in the active
statewith theGTPanalogueGppNHp (PDBentry 2bme
[130]) and in the inactive GDP-bound state (PDB entry
2bmd [130]).
Residue Phe72 is located at the start of α-helix
H2 in the switch 2 region of Rab4a and has the transFig. 7. Improving the binding interface between Hercep
Fab light chain of Herceptin (pink) with a single hydrogen bond
1n8z. Flipping Asn30 and re-fitting Thr31 together with small ad
bonding network between the proteins containing four hydroge
Thr31 and Asn30 side chains. The 2mFo − DFc map is shownconformation in the GppNHp-bound state. The trans
conformation is also present in the GDP-bound struc-
ture. Recently, a method was created to detect cis
peptides erroneously modelled as trans peptides [105].
The method predicted that Phe72 in the GDP-bound
state should have beenmodelled as a cis peptide rather
than a trans peptide and this prediction was validated by
re-refinement [105] (see Fig. 9).tin and HER2. Left: detail of PDB entry 1n8z showing the
to HER2 [126]. Right: the PDB_REDO optimised version of
justments to the local HER2 side chains reveal a hydrogen
n bonds and one hydrogen bond that correctly positions the
up to 1.5 Å from the protein fragments.
Fig. 8. Water and potassium rather than magnesium in the α-kinase domain of myosin heavy chain kinase. Left:
Mg901 should be replaced by a water molecule in PDB entry 3lkm [128] according to metal validation software [97]. The
contact distance is shown in angstroms (Å). Right: the site occupied by Mg902 in 3lkm should be occupied by a potassium
ion instead [97]. The two water molecules (bottom right) should be replaced by ethylene glycol [97]. The 2mFo − DFc maps
are shown at a contour level of +1.5 σ.
1384 Review: Better Structure ModelsAlthough it cannot be excluded that the cis
conformation was induced by crystallisation, these
findings strongly suggested that Arg71–Phe72
trans–cis isomerisation plays a role in the discrim-
ination between different effector proteins that
hitherto was unknown.Example 7—Peroxiredoxin active site in
MD simulations
The human pathogen Mycobacterium tuberculo-
sis is responsible for millions of deaths every year
[131]. The bacterium gets engulfed by host macro-
phages, exposing it to a toxic environment of reactive
oxygen species, but it can survive these hostile
conditions by expressing peroxidases [132] such as
the one-cysteine peroxiredoxin AhpE [133]. When
AhpE scavenges reactive oxygen species, Cys45 is
sulfenylated. The sulfenic acid form of Cys45 can be
reduced by mycothiol or mycoredoxin-1 [134].
Palló et al. carried out MD simulations to study
the active site in atomic detail (personal communi-
cation, 2015; Palló A, van Bergen L, Alonso M,
Nilsson L, de Proft F, & Messens J. The revisited
AhpE structures affect the MD simulations of the
Mycobacterium tuberculosis one-cysteine peroxir-
edoxin). MD simulations are sensitive to errors in
macromolecular structures. Palló et al. observed
that simulations were not stable when PDB entry
1xxu [133] was used as a starting structure. Theα-helix that contains Cys45 started to unwind
during a 30-ns simulation. In contrast, simulations
using the PDB_REDO structure were stable,
probably because of the optimised hydrogen
bond network in the active site (Fig. 10).
The improved AhpE structure model allows for
mechanistic studies of the M. tuberculosis peroxir-
edoxin at atomic detail.Example 8—Malaria drugs
Plasmodium falciparum is the parasite that
causes malaria, which still ranks as one of the
diseases with the highest death toll. The parasitic
aspartic acid protease plasmepsin II is involved in
degradation of the host cell haemoglobin [135] and
is therefore an interesting drug target. The struc-
ture of plasmepsin II was thought to be determined
in complex with two inhibitors rs367 and rs370 in
PDB entries 1lee and 1lf2, respectively [136]. The
difference between the two inhibitors is the position
of the amino group that ismeta in the benzamide in
rs367 and para in rs370. The structures in 1lf2 and
1lee are nearly identical with an all-atom RMS
deviation of just 0.32 Å.
Inspection of the electron density around the
inhibitor in 1lee suggests that the amino group
should be modelled as a para-substituent (see Fig.
11), which meant that both 1lee and 1lf2 contained
the same inhibitor, likely as the result of a mix up
Fig. 9. Rab4a trans–cis flip in the switch 2 region of Rab4a. Left: the peptide between Arg71 (side chain not shown
for clarity) and Phe72 in PDB entry 2bmd [130] has the trans conformation but deviating local geometry and the electron
density around the peptide bond suggest that the peptide should have the cis conformation. Right: the cis peptide fits the
experimental data much better. The 2mFo − DFc maps are shown at a contour level of +1.5 σ.
1385Review: Better Structure Modelsduring the structure determination. The detection of
this mix up is currently beyond the capabilities of
validation routines and instead relies on critical
inspection of the electron density by the crystal-
lographer, which should be a key step in determin-
ing structures with ligands [115].
Docking studies on both structures [137] led to
new candidate inhibitors, but it is a pity that twice as
much time and computing power was used as
needed. Low-throughput rational drug design pro-
jects aimed at better inhibitors will suffer even more
from this para–meta error.Fig. 10. Active site of one-cysteine peroxiredoxin AhpE
helix α2 that unwinds during MD simulations based on PDB
flipped Gln46 side chain optimises the local hydrogen bonding
stability of MD simulations.Example 9—The Chemistry of Autotaxin
Inhibitors
Autotaxin (ATX; also known as ENPP2) is a
secreted enzyme that converts lysophosphatidyl-
choline into the lipid signalling molecule lysopho-
sphatidic acid. The ATX–lysophosphatidic acid
signalling axis is involved in normal physiology and
pathophysiology [138]. ATX expression is found to
be up-regulated in several carcinomas and is
implicated in motility of tumour cells [138] and, as
such, a target for developing drugs for cancerwith Cys45 in the reduced state. Left: Cys45 is located in
entry 1xxu [133]. Right: in the PDB_REDO structure, the
network with Asp50, Trp80, and Ser84 and increases the
Fig. 11. The benzamide moiety of the plasmepsin II
inhibitor in PDB entry 1lee [136]. The electron density
suggests that the amino group of the benzamide moiety
should be modelled para instead ofmeta. The 2mFo − DFc
and mFo − DFc maps are shown up to 1.5 Å and 2.5 Å
from the displayed inhibitor fragment, respectively. The
2mFo − DFc map is shown at +2 σ.
1386 Review: Better Structure Modelstreatment. One class of ATX inhibitors is based on a
boronic acid moiety that binds covalently to the
hydroxyl group of active-site residue Thr209 [139].
In this process, the hybridisation of the boron atomFig. 12. Correcting chemical representation of boron. Le
site of ATX (PDB entry 3wax [140], pink). The boron atom (grey
benzene moiety (orange broken lines) but not covalently bo
molecule related by crystal symmetry. Right: PDB_REDO-opti
and a covalent bond to Thr209. Manually generated restrain
inhibitor–ATX interaction.changes from sp2 to sp3, analogous to the formation
of tetrahydroxyborate from boric acid.
The structure of ATX with inhibitor 3BoA (PDB entry
3wax [140]) shows the problem of dealing with
changing chemistry in refinement. Although the au-
thors correctly report that 3BoA is covalently bound to
Thr209, this is not reflected in the structure model
because the distance between the boron atom and the
Thr-Oγ1 is 2.28 Å and the boron atom is sp2 hybridised
in the model (Fig. 12). The structure of ATX and 4BoA
from the same study (PDB entry 3way) suffers from the
same problem. In the PDB_REDO 3wax structure
model, the B-Oγ1 distance is 1.38 Å and the boron
atom is properly sp3 hybridised. The earlier published
structure of ATX and the boronic acid inhibitor HA155
also shows the correct geometry (PDB entry 2xrg
[139]), but the other structure models may lead to
misinterpretation of the ligand binding interaction.
Correct chemical representation is crucial for the
design or optimisation of ATX inhibitors.Example 10—Xylose isomerase active
site
Figure 13 shows the active-site pocket of xylose
isomerase, an enzyme that catalyses the intercon-
version between D-xylose and D-xylulose and be-
tween D-glucose and D-fructose [141]. The reaction
involves hydrogen transfer and two magnesium ions.ft: fragment of the inhibitor 3BoA (white) bound to the active
) is modelled as sp2 hybridised and covalently bound to the
und to Thr209. The blue Glu576 is from a different ATX
mised version of 3wax with the correct boron hybridisation
ts are required to deal with the complex chemistry of the
Fig. 13. Threading errors around the active-site
pocket of xylose isomerase. The one-letter amino acid
codesare shownon top of theCα trace.Orange: 3xia [142] is
mis-threaded at many locations. Cyan: 1xya [141]. Magne-
sium and a hydroxyl ion are shown as yellow and red
spheres, respectively. This figure was prepared with
YASARA [144].
1387Review: Better Structure ModelsPDB entry 3xia [142] was superseded by 1xya [141]
after, for example, packing quality analysis [21] and
inspection of the electron density revealed that many
amino acidsweremis-identified ormis-threaded. 1xya
is in much better agreement with the biochemistry.
Neutron diffraction later also showed that a water
molecule rather than a hydroxyl ion should have been
modelled in the active site [143].
The comparison of 3xia and 1xya clearly shows
that a mis-threaded structure model can place theTable 2. Macromolecular structure validation facilities
Facility
PDB_REDO [109,145] Constructive v
WHAT_CHECK [43,112] E
MolProbity [58,68]
PROCHECK [41] P
PDB validation server [54,61] Pre
QMEAN [62,146]
ProSA [23,147] Knowledge-based potentials of m
CheckMyMetal [97]
VHELIBS [82] Va
ValLigURL [83]
Twilight [85] L
PSVS [148] Metaswrong amino acids at the wrong positions. Correct
answers to biological questions related to the
function of the protein can only be obtained from
correctly threaded structure models. We are reason-
ably certain that the work of the X-ray VTF will lead to
the situation that structures such as 3xia will not be
passed on to the life science community. Fortunate-
ly, the deposition of reflection data is mandatory
now. The problems described here might be
identified more readily when experimental data are
available.Validation-related facilities
Many facilities to validate protein structures exist.
Several have been mentioned in this article already.
Table 2 lists a series of protein structure validation
facilities that are freely accessible on the internet
[112]. Of course, the validation modules mentioned
here can be used not only for checking X-ray
structure models but also for checking structure
models derived by NMR, electron microscopy, or in
silicomodelling. Validation methods specific to NMR
and electron microscopy and methods based on
structure factors are beyond the scope of this article.
Much of the validation work has found its way
already into the PDB_REDO project ||. Crystallogra-
phers can freely use the PDB_REDO server¶ to
optimise their work-in-progress structure models.Concluding remarks
Today, experimental data deposition is an obliga-
tory aspect of structure deposition in the PDB.
Indeed, data are missing for only one recent crystal
structure entry deposited in the PDB in 2014 (4ux6
[149]). We congratulate those who have set a great
example by depositing datasets that were missing
for 30 years (e.g., for the structural studies of
leghaemoglobin by Steigemann and co-workers
[150]).Description
alidation by re-refinement and partial re-building
xtensive macromolecular validation
Macromolecular validation
rotein structure geometry checks
- and post-validation of PDB entries
Global model-quality estimation
ean force to evaluate macromolecular structure model accuracy
Validation of metal-binding sites
lidation of ligands and binding sites
Ligand validation
igand visualisation and validation
erver that includes many of the above
1388 Review: Better Structure ModelsThe highly improbable features in Schwarzenba-
cher's structure model of the birch pollen allergen
Bet v 1 protein [52] were detected [51] by studying
anomalies in the statistics of PDB_REDO's model
optimisation. Extremely unusual features, such as
those shown in Fig. 2a, might remain undetected for
longer if the corresponding reflection data are not
made available.
Deposition of reflection data was not mandatory until
recently (February 1, 2008). We believe that it is
beneficial if missing reflection datasets are recovered
anddeposited becausewebelieve that transparencyby
depositors and validation by others will lead to a
higher-quality archive. Not necessarily because we
expect any cases of fraud or gross error in PDB entries
that do not have deposited reflection data but because
the validation of alternative structure models against
reflection data allows post-deposition model improve-
ments. The oldest structure models in the PDB can be
improved using today's methods. The average Mol-
Probity clash score of the oldest models, for example,
was at the 48th percentile relative to MolProbity's
reference set and ended up at the 80th percentile
after re-refinement and re-building [108]. As better
computational crystallographic techniques continue to
be developed, the quality of the archive can be
improved ever further.
Aswith anyscientific endeavour, validationofmodels
and data is a component of sound application of the
scientificmethod.Macromolecular structures solved by
X-ray crystallography are the result of experiment-
s—performed by humans—and may thus contain
experimental and human errors.
Although there were a small number of individuals
resistant to validation for many years [53], the majority
were in favour. Research into geometric, thermody-
namic, electrostatic, and many other aspects of
protein structures has continued, and the series of
recent highly visible cases of very unlikely structures
that had to be retracted have further anchored
validation tools in the protein structure solution
pipelines.
Our experiences with PDB_REDO lead us to
conclude that more emphasis should be placed on
the deposition of raw data (diffraction images and/or
unmerged reflections) and experiment-related meta-
data. A computer readable description of the crystal-
lisation conditions is an important example. This will
allow the development of more and better tools aimed
at making the best possible structure models. We also
suggest that referees of articles mentioning novel PDB
entries should receive a structure validation report,
without having to ask for it, rather than be made to
assess a structure model's quality from the very limited
information in a manuscript and its supplemental data.
To this end, we reiterate the importance for crystallog-
raphers to finish and deposit their structuremodels and
the reflection data before submitting a manuscript,
rather than just before it is accepted [151]. Current PDBdeposition proceduresmake this possible and have the
option to “suppress entry titles at the time of submission
to the PDB until the structure is released” [152]. In the
long term, a validation report can be accompanied by a
report from PDB_REDO or another automated model
optimisation procedure that shows whether the model
can be improved beyond the effort delivered by the
depositor. This will certainly further improve the average
quality of PDB structure models. These structure
models, like all scientific results, are predestined to be
re-used by others. Therefore, a higher average model
quality will also improve the quality of many projects
directed at answering important biomedical questions.Acknowledgements
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